Rare Daily Staff
BridgeBio Pharma and Cincinnati Children’s Hospital Medical Center said they are entering into a research collaboration to identify and develop therapies for genetic diseases.
The partnership will combine BridgeBio’s strengths in therapeutic development for diseases of high unmet need with Cincinnati Children’s clinical and researcher expertise.
The company said as a global research center of excellence, Cincinnati Children’s represents an ideal partner and reinforces BridgeBio’s commitment to collaborating with leading researchers toward the mutual goal of discovering new therapies targeting genetic diseases at the source.
“We hope we can help advance the mission by partnering to move therapies forward to patients,” said Neil Kumar, co-founder and CEO of BridgeBio.
Under the terms of the agreement, BridgeBio will have the opportunity to sponsor and collaboratively develop selected research programs. The agreement represents a flexible model that facilitates accelerated genetic disease research.
“This collaboration exemplifies Cincinnati Children’s commitment to accelerating discoveries towards commercialization through win-win academic-industry partnerships,” said Mike Pistone, director of acceleration for Cincinnati Children’s Innovation Ventures, the group managing the program.
November 11, 2018
Photo: Neil Kumar, CEO of BridgeBio